Trial reportJournal of clinical pharmacology2026
Concentration-QTc Analysis Supporting Thorough QT Study Waiver for Forvisirvat: Electrocardiogram Assay Sensitivity Demonstrated via Meal Effect.
Trial report in Journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Concentration-QTc analysis from Phase 1 studies is increasingly used to evaluate QTc prolongation risk as an alternative to thorough QT (TQT) studies. According to International Conference on Harmonization E14 documents, such analyses should include exposures at twice the highest clinically relevant exposure instead of a positive control to establish electrocardiogram (ECG) assay sensitivity; however, achieving this may be challenging when the highest dose in Phase 1 studies is restricted for various reasons. This study evaluated the QTc prolongation risk of forvisirvat via concentration-QTc analysis and demonstrated ECG assay sensitivity via the well-described meal effect. A double-blind, randomized, placebo-controlled, single ascending dose study evaluated the effect of forvisirvat on ECG parameters following single oral doses up to 80 mg in 32 healthy adults. Time-matched plasma forvisirvat concentrations and 12-lead ECG data were collected. The prespecified linear mixed-effects model assessed the impact of forvisirvat on baseline- and placebo-adjusted QT interval corrected by the Fridericia method (ΔΔQTcF). ECG assay sensitivity was established by prospectively evaluating the postprandial QTcF shortening. The two-sided 90% confidence interval (CI) for the model-predicted ΔΔQTcF was below 10 ms up to the maximum observed plasma concentration of 703 ng/mL. Meal-induced QTcF shortening was -6.38 ms (95% CI, -8.51 to -4.26) at 4 h after the standardized lunch, with the two-sided 95% CI below 0. Forvisirvat showed no QTcF prolongation, and ECG assay sensitivity was confirmed via meal-induced QTcF shortening. These results supported regulatory acceptance of a TQT study waiver by the Japanese Pharmaceuticals and Medical Devices Agency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.